# US 4,397,870 A · Process for prolonging retention of emulsion particles in the bloodstream

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 4,397,870 A
- Document ID: US4397870A
- Status: Granted
- Kind: A
- Application number: 06/402,449
- Filed: 1982-07-27
- Granted: 1983-08-09
- Earliest claimed: 1982-07-27
- Assignees: University of Pennsylvania
- Inventors: Henry A. Sloviter
- Web page: https://patentgrep.com/patent/US4397870A

## CPC

- A61K 9/0026: {Blood substitute; Oxygen transporting formulations; Plasma extender}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The retention of coated particles previously infused into the bloodstream of animals may be prolonged by one or more injections of coating substance. For example, the retention of an artificial blood composition comprising emulsified lecithin-coated perfluoro compounds may be prolonged by injection of lecithin.

## Claims

### Claim 1

A process for prolonging the stability and retention of coated water insoluble oxygen transporting particles infused into the bloodstream of animals and humans comprising at least one subsequent injection of the same substance which coats the infused particles.

### Claim 2 (depends on 1)

A process according to claim 1 wherein the infused particles are present in an emulsion in which the emulsifier is a different substance than the particle-coating substance.

### Claim 3 (depends on 1)

A process according to claim 1 wherein the infused particles comprise artificial blood.

### Claim 4 (depends on 3)

A process according to claim 3 wherein the artificial blood is an emulsion comprising an oxygen-transporting perfluoro compound, an emulsifier which coats the perfluoro compound, and a physiologically acceptable medium.

### Claim 5 (depends on 4)

A process according to claim 4 wherein the artificial blood composition additionally contains a fatty acid emulsifier adjuvant.

### Claim 6 (depends on 3)

A process according to claim 3 wherein the perfluoro compound is selected from the group consisting of perfluorodecalin, perfluoromethyldecalin, perfluorotripropylamine, and perfluorotributylamine.

### Claim 7 (depends on 4)

A process according to claim 4 wherein the emulsifier is selected from the group consisting of lipid and high molecular weight nonionic surfactants.

### Claim 8 (depends on 7)

A process according to claim 7 wherein the emulsifier is a phosphalipid.

### Claim 9 (depends on 8)

A process according to claim 8 wherein the emulsifier is lecithin.

### Claim 10 (depends on 7)

A process according to claim 7 wherein the emulsifier is a polyoxyethylene-polyoxypropylene copolymer.

### Claim 11 (depends on 7)

A process according to claim 7 wherein the amount of perfluoro compound in the infused emulsion is up to about 75% (w/v).

### Claim 12 (depends on 7)

A process according to claim 7 wherein the amount of emulsifier in the infused emulsion is about 7-9% (w/v).

### Claim 13 (depends on 7)

A process according to claim 7 wherein the physiologically acceptable medium is isotonic solution.

### Claim 14 (depends on 13)

A process according to claim 13 wherein the isotonic solution as selected from the group consisting of Tyrode solution, Ringer's solution, lactated Ringer's solution, and Ringer's solution containing glucose.

### Claim 15

A process for prolonging the stability and retention of a perfluoro compound emulsion in the circulation useful as an artificial blood containing about 30-75% (w/v) perfluoro compound and about 7-9% (w/v) lecithin comprising at least one subsequent injection of lecithin into the circulation.